WO2021107713A1 - Procédé de diagnostic de la sclérose latérale amyotrophique sur la base d'un marqueur de mutation du gène lats1 - Google Patents

Procédé de diagnostic de la sclérose latérale amyotrophique sur la base d'un marqueur de mutation du gène lats1 Download PDF

Info

Publication number
WO2021107713A1
WO2021107713A1 PCT/KR2020/017169 KR2020017169W WO2021107713A1 WO 2021107713 A1 WO2021107713 A1 WO 2021107713A1 KR 2020017169 W KR2020017169 W KR 2020017169W WO 2021107713 A1 WO2021107713 A1 WO 2021107713A1
Authority
WO
WIPO (PCT)
Prior art keywords
lats1
gene
mutant
lateral sclerosis
amyotrophic lateral
Prior art date
Application number
PCT/KR2020/017169
Other languages
English (en)
Korean (ko)
Inventor
기창석
김영은
오기욱
김승현
Original Assignee
주식회사 녹십자지놈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 녹십자지놈 filed Critical 주식회사 녹십자지놈
Publication of WO2021107713A1 publication Critical patent/WO2021107713A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2878—Muscular dystrophy

Definitions

  • the present invention relates to a method for diagnosing amyotrophic lateral sclerosis based on a LATS1 gene mutation, and more particularly, to a method and marker for diagnosing and predicting amyotrophic lateral sclerosis by detecting a LATS1 mutant gene or a LATS1 mutant protein encoded by it. it's about
  • ALS Amyotrophic lateral sclerosis
  • Lou Gehrig disease is a disease in which only motor neurons are selectively killed. cells), the brain stem (brainstem), and the lower motor neurons of the spinal cord are all gradually destroyed. Clinical symptoms start with slowly progressive weakness and atrophy of the extremities, and as the disease progresses, it is a fatal disease that eventually leads to death within a few years of respiratory muscle paralysis. It is known that about 1 to 2 people per 100,000 people a year develop Lou Gehrig's disease.
  • Amyotrophic lateral sclerosis is a fatal disease with the fastest symptom progression among motor neuron diseases (MND) and is known to have an average lifespan of less than 4-5 years, and as the disease progresses, death from respiratory failure and other complications due to respiratory muscle paralysis. will do Although there is no medical treatment that can cure it yet, drug treatment to slow the progression of symptoms, prevention and management of other complications, etc., have a great influence on the patient's prognosis, so early diagnosis is the most important for prevention and treatment ( Seoul National University Hospital medical information).
  • MND motor neuron diseases
  • ALS Although the cause of ALS is not yet known, several hypotheses have been proposed so far. About 5-10% of all ALS patients are known to have familial muscular atrophic familial sclerosis, and of these, mutations in the causative gene on chromosome 21 are confirmed in about 20% of families. So far, eight genes have been reported to cause familial ALS. In addition, in sporadic ALS, which is not hereditary, apoptosis (apoptosis, apoptosis, a phenomenon in which cells die by themselves under the control of genes) by excitotoxicity is thought to play an important role. Other hypotheses that a special virus is the cause and the action of environmental toxins have been suggested as the cause of ALS, but there is no direct evidence yet (Medical Information of Seoul National University Hospital).
  • Tests for the diagnosis of amyotrophic lateral sclerosis include blood tests, electromyography, brain and spinal cord imaging tests, and in some cases, muscle biopsy and genetic tests are additionally performed. After diagnosis, progress status and prognosis are evaluated, and appropriate drug treatment and rehabilitation treatment are performed according to the stage of the disease.
  • genes that cause ALS superoxide dismutase 1 (SOD1), transactive response DNA-binding protein (TARDBP), fused in sarcoma (FUS), chromosome 9 open reading frame 72 (C9orf72), etc. are well known.
  • SOD1 superoxide dismutase 1
  • TARDBP transactive response DNA-binding protein
  • FUS fused in sarcoma
  • C9orf72 chromosome 9 open reading frame 72
  • Another object of the present invention is to provide a LATS1 mutant gene as a novel biomarker.
  • Another object of the present invention is to provide a LATS1 mutant protein as a novel biomarker.
  • Another object of the present invention is to provide a composition for diagnosis of amyotrophic lateral sclerosis.
  • Another object of the present invention is to provide a kit for diagnosis of amyotrophic lateral sclerosis.
  • the present invention relates to amyotrophic lateral sclerosis (ALS) comprising detecting a LATS1 (Large Tumor Suppressor Kinase 1) mutant gene or a LATS1 mutant protein encoded by the LATS1 mutant gene in an isolated biological sample.
  • ALS amyotrophic lateral sclerosis
  • the present invention also provides a mutant LATS1 (Large tumor suppressor kinase 1) mutant gene comprising at least one of SNV, Indel and CNV as a diagnostic marker for amyotrophic lateral sclerosis, and a mutant LATS1 protein encoded by the gene.
  • LATS1 Large tumor suppressor kinase 1
  • the present invention also provides a composition for diagnosis of amyotrophic lateral sclerosis comprising an agent capable of detecting a large tumor suppressor kinase 1 ( LATS1 ) mutant gene or a LATS1 mutant protein encoded by a mutant LATS1 gene.
  • LATS1 large tumor suppressor kinase 1
  • the present invention also provides a kit for diagnosis of amyotrophic lateral sclerosis, comprising an agent capable of detecting a large tumor suppressor kinase 1 ( LATS1 ) mutant gene or a LATS1 mutant protein encoded by a mutant LATS1 gene.
  • LATS1 large tumor suppressor kinase 1
  • the present invention also provides a diagnostic use for amyotrophic lateral sclerosis of a large tumor suppressor kinase 1 ( LATS1 ) mutant gene comprising at least one of SNV, Indel and CNV and a LATS1 mutant protein encoded by the gene.
  • LATS1 large tumor suppressor kinase 1
  • LATS1 Large tumor suppressor kinase 1
  • ALS amyotrophic lateral sclerosis
  • 1 is a graph showing the expression level of the LATS1 gene for each tissue.
  • Figure 2 is the result of performing exome sequencing of amyotrophic lateral sclerosis patients and parents. Mutations not present in normal parents were found in the LATS1 gene.
  • Amyotrophic lateral sclerosis is a neurodegenerative disease that occurs in adults due to progressive loss of motor neurons in the cortex, cerebral cortex, and spinal cord. About 10% of patients have familial ALS with a family history, and about 90% of patients develop sporadically without a family history. To date, mutations in several genes, including SOD1, TARDBP, FUS, and C9orf72, have been reported as the cause of ALS, but the genetic cause is unknown in 1/3 of familial ALS patients and about 90% of sporadic ALS patients. Recently, with the discovery of a new gene related to the onset of amyotrophic lateral sclerosis, it has been revealed that this disease is related to frontotemporal dementia and various types of muscle diseases and degenerative diseases. There are problems in diagnosing or applying to treatment.
  • Amyotrophic lateral sclerosis is a disease that does not currently have an effective treatment method, and is rapidly invented and progressing with an average lifespan of less than 4-5 years. When diagnosed by clinical symptoms, treatment or improvement is almost impossible. Therefore, it is important to diagnose the disease at an early stage of onset through early diagnosis such as prenatal diagnosis.
  • the present inventors tried to identify a gene related to amyotrophic lateral sclerosis and the SNV of the gene for early diagnosis of amyotrophic lateral sclerosis.
  • sequencing analysis was performed after extracting genomic DNA from blood samples for patients with sporadic amyotrophic lateral sclerosis and their parents.
  • ALS-FTD causative gene or related gene for the differential diagnosis of amyotrophic lateral sclerosis, HSP and other disease genes for the differential diagnosis of amyotrophic lateral sclerosis No previously reported mutations were found.
  • one novel mutation was found in the analysis through Sanger sequencing of the patient and parent, which was the deletion of the 2790th base from the nucleotide sequence of the LATS1 gene, and the 930th amino acid leucine was substituted with phenylalanine and it was confirmed that it is a frameshift mutation in which synthesis ends at the 27th (956th). It was confirmed that the mutation was a novel mutation not found in dbSNP, 1000 Genome Project, gnomAD, and KRGDB, which is the normal control group Korean data, and that the mutation could be used as a new diagnostic marker for amyotrophic lateral sclerosis.
  • the present invention provides, in an isolated biological sample, a large tumor suppressor kinase 1 ( LATS1 ) mutant gene or amyotrophic lateral sclerosis comprising the step of detecting a mutant LATS1 protein encoded by the mutant LATS1 gene. It relates to a method of providing information for the diagnosis of lateral sclerosis: ALS.
  • LATS1 large tumor suppressor kinase 1
  • LATS1 Large tumor suppressor kinase 1
  • amyotrophic lateral sclerosis comprising the step of detecting a mutant LATS1 protein encoded by the mutant LATS1 gene : ALS) diagnosis method.
  • amyotrophic lateral sclerosis may be diagnosed.
  • Amyotrophic lateral sclerosis is largely classified into two types depending on the cause, and is divided into a familial type and a sporadic type that occurs alone. Familial ALS accounts for about 10% of all cases, and mutations in one or more genes are the cause. About 15% of familial patients develop the disease due to a mutation in the SOD1 gene, and the disease can occur even if a defective gene is inherited from one parent in an autosomal dominant form. On the other hand, the cause of sporadic ALS has not been specifically identified. Heavy metals such as aluminum, mercury, and lead used in dental rods, which are environmental factors, are suggested as the cause, but it is not clear.
  • amyotrophic lateral sclerosis may be characterized as familial or sporadic.
  • Diagnosis of amyotrophic lateral sclerosis is primarily based on clinical symptoms. Damage to both upper and lower motor nerves is characteristic. In the early stages, damage to only the upper motor nerve may appear, but generally, damage to the lower motor nerve occurs within 3 to 5 years after the onset. Diagnosis by clinical symptoms of amyotrophic lateral sclerosis is diagnosed by the condition exclusion method after the primary clinical findings because the causes and treatment methods can appear similar to those of completely different myopathy. In general, based on the patient's history and neurological examination, nerve conduction velocity test (NCV), muscle tissue biopsy, blood test, urine test, cerebrospinal fluid test, cervical spine X-ray and magnetic resonance imaging test, electromyography (EMG), etc. are performed to make a diagnosis For example, amyotrophic lateral sclerosis is excluded from the diagnosis if these symptoms are present because it is rarely accompanied by ocular movement disorders, sensory disorders, bladder and anal disorders, or intellectual disorders.
  • NCV nerve conduction velocity test
  • EMG electromy
  • diagnosis refers to determining a subject's susceptibility to a particular disease or disorder, determining whether a subject currently has a particular disease or disorder, or having a particular disease or disorder. determining a subject's prognosis, or therametrics (eg, monitoring a subject's condition to provide information about treatment efficacy). For the purposes of the present invention, diagnosis is to determine whether or not (risk) the development of amyotrophic lateral sclerosis.
  • LATS1 large tumor suppressor kinase 1 gene was identified as a gene candidate causing amyotrophic lateral sclerosis.
  • the present inventors discovered a novel frameshift mutation c.2790del (p.Leu930Phefs*27) of the LATS1 gene in the sALS trio.
  • the mutation in the LATS1 gene was not present in 1722 same-race normal controls. And no corresponding mutations were reported in dbSNP, 1000 Genome Project (all and East Asians) and gnomAD.
  • the LATS1 mutant gene refers to a mutated LATS1 gene, for example, the mutation is a single nucleotide variant (Single Nucleotide variant: SNV), insertion or deletion (Indel) and gene copy number mutation (Copy-) number variation, CNV) may be any one or more selected from the group consisting of, but is not limited thereto, and refers to all genetic mutations recognized by those skilled in the art.
  • the mutation of the large tumor suppressor kinase 1 (LATS1) mutant gene may be a single nucleotide variant (SNV), insertion or deletion, and more preferably, may be a deletion.
  • the LATS1 (Large tumor suppressor kinase 1) mutant gene may be characterized in that the 2790th nucleotide is deleted from the nucleotide sequence of SEQ ID NO: 1.
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that a frame shift occurs by insertion or deletion of one or more bases.
  • LATS1 gene is located on chromosome 6q25.1, consists of 8 exons, and encodes 1,130 amino acids.
  • LATS1 protein is a putative serine/threonine kinase that is involved in the initial meiosis process together with CDC2 kinase that regulates the cell division cycle, and is known to act as a tumor suppressor gene.
  • LATS1 is expressed in various tissues, including the brain. The expression level for each tissue of the LATS1 gene is shown in FIG. 1 .
  • the LATS1 gene includes all homologous genes found in all animals including humans, and the cDNA sequence of the normal human LATS1 gene confirmed in an embodiment of the present invention is the same as SEQ ID NO: 1 (NM_004690.4) Homo sapiens large tumor suppressor kinase 1 (LATS1), transcript variant 1, mRNA), confirmed in an embodiment of the present invention
  • LATS1 large tumor suppressor kinase 1
  • the amino acid sequence of the normal human LATS1 protein is the same as SEQ ID NO: 2 (NP_004681.1 serine/threonine-protein kinase LATS1) isoform 1 [Homo sapiens]), but not limited thereto.
  • the information providing method or the diagnostic method is characterized in that the gene is obtained and amplified from a sample isolated from an individual, and the occurrence of mutation in the LATS1 gene is analyzed using sequencing data of the amplified product. can be done with
  • amplification refers to a reaction that amplifies a nucleic acid molecule.
  • Various amplification reactions have been reported in the art, including polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR), ligase chain reaction (LCR) Gap-LCR, repair chain reaction , transcription-mediated amplification (TMA), self sustained sequence replication, selective amplification of target polynucleotide sequences, consensus sequence priming polymerase chain reaction (consensus) sequence primed polymerase chain reaction (CP-PCR), arbitrarily primed polymerase chain reaction (AP-PCR), nucleic acid sequence based amplification (NASBA), strand displacement amplification (strand displacement amplification) and loop-mediated isothermalamplification (LAMP).
  • PCR is the most well-known nucleic acid amplification method, and many modifications and applications thereof have been developed. For example, touchdown PCR, hot start PCR, nested PCR, and booster PCR have been developed by modifying traditional PCR procedures to enhance the specificity or sensitivity of PCR.
  • real-time PCR differential display PCR (DD-PCR), rapid amplification of cDNA ends (RACE), multiplex PCR, inverse polymerase chain reaction (inverse polymerase chain reaction) Chain reaction: IPCR), vectorette PCR and TAIL-PCR (thermal asymmetric interlaced PCR) have been developed for specific applications.
  • DD-PCR differential display PCR
  • RACE rapid amplification of cDNA ends
  • IPCR inverse polymerase chain reaction
  • TAIL-PCR thermal asymmetric interlaced PCR
  • Single Nucleotide Variant refers to a mutation that shows a difference in single nucleotide sequence among genomic mutations.
  • Single nucleotide polymorphism (SNP) and point mutation are here can occur in somatic cells of any frequency
  • Single nucleotide alterations in somatic cells eg, caused by cancer
  • Single-nucleotide alterations Single nucleotide polymorphisms are identical in the genome of multiple individuals.
  • a specific nucleotide sequence at a position is changed to another nucleotide and expressed as a different trait, and it is the most common form of genetic mutation in the human genome.
  • Single nucleotide polymorphisms generally occur with a frequency of 1% or more of the population, If it is less than 1%, it is classified as a mutation Point mutation is a substitution, insertion, or deletion of one base sequence, and can prevent or modify the production of a specific protein.
  • Single nucleotide mutations are classified according to their location and function in the genome. In addition, according to the presence or absence of amino acid sequence mutation, it is classified into synonymous SNV (sSNV) that does not cause amino acid sequence mutation and nonsynonymous SNV (nsSNV) that does not cause amino acid sequence mutation.
  • sSNV synonymous SNV
  • nsSNV nonsynonymous SNV
  • indels can cause more serious mutations than substitutions. In the case of indel, a frame shift of the amino acid sequence sequence is induced, so that the amino acid translated after the SNV is changed.
  • the SNV present in the coding exon region is called the coding SNV (cSNV), and has the same ratio as the intron, 5' and 3' untranslated regions (UTR).
  • the SNV present in the coding region is called non-coding SNV (ncSNV).
  • SNP and “SNV” may be used interchangeably, and may be used as the same meaning as “SNV of LATS1 gene” or " SNP of LATS1 gene”.
  • Single Nucleotide Polymorphism refers to a single nucleotide (A, T, C, or G) in the genome that differs between members of a species or between chromosomes of an individual. Refers to the diversity of DNA sequences Within a population, SNPs can be assigned to a minor allele frequency (MAF; the lowest allele frequency at a locus found in a particular population) Variations exist within the human population, and a single SNP allele common in a geological or ethnic group is very rare. A single base is a change (replacement), deletion (deletion) or addition ( The SNP may cause an inframe shift.
  • a single base is a change (replacement), deletion (deletion) or addition ( The SNP may cause an inframe shift.
  • SNV or SNP analysis Various methods are used for SNV or SNP analysis. Most of the methods developed and used so far are based on the PCR method and mainly analyze a limited number of samples, but analyze a large number of SNPs at the same time using a DNA array or use ultra-precision analysis equipment such as MALDI-TOF. Analysis methods are also widely used. According to the principle of SNP genotyping, there are four types: Allele-Specific Hybridization, Primer Extension, Allele-Specific Oligonucleotide Ligation, and Cleavage depending on the difference between the sample preparation method and the search method.
  • SSCP Single Strand Conformation Polymorphism
  • AFLP Amplified Fragment Length Polymorphism
  • RFLP Restriction Fragment Length Polymorphism
  • RAPD Random Amplified Polymorphic DNA
  • AS-PCR Allele-PCR Specific PCR
  • Insertion or deletion means that one or more nucleotides are inserted or deleted in a gene.
  • Indel in SNV means that one nucleotide is inserted or deleted, and "insertion or deletion (Indel)" can be used to include it.
  • CNV Codon-number variation
  • the sequencing may be characterized by Sanger sequencing or next generation sequencing (NGS).
  • NGS next generation sequencing
  • novel mutations causing substitution of all amino acids according to the filtering criteria were evaluated through Sanger sequencing of DNA. All exon and exon-intron boundaries of the target gene were amplified by PCR using primers (Table 6).
  • Sanger sequencing analysis is a method of analyzing a nucleotide sequence through DNA chain termination using dideoxynucleotide triphosphate (ddNTP).
  • ddNTP dideoxynucleotide triphosphate
  • Sanger sequencing is very simple and less toxic, so it has spread rapidly compared to the Maxam-Gilbert method developed at the same time (Maxam and Gilbert, 1977), and other methods have been modified and developed in this method. .
  • Sanger sequencing includes modifications and advanced analysis methods known to those skilled in the art, in addition to the first known method.
  • NGS next-generation sequencing
  • next-generation sequencing corresponds to the second-generation technology in terms of automation.
  • NGS is a name called to distinguish it from the first automation device before and to distinguish it from the Next NGS device (also referred to as next-generation or third-generation NGS) that was created later.
  • Next NGS Next NGS device
  • next-generation or third-generation NGS next-generation or third-generation NGS
  • NGS is used in a broad sense encompassing all of the sequencing technology after the automated Sanger sequencing technology.
  • “next-generation sequencing” is used in a broad sense encompassing all sequencing techniques after Sanger sequencing technology.
  • a sequencing method that does not amplify a gene includes, but is not limited to, a single molecule, real-time (SMRT), Oxford Nanopore sequencer, and the like.
  • the step of detecting the LATS1 mutant gene may LATS1 mutation using primers for the gene, it is also possible to use a pair (pair) or more primer sets.
  • the primer can be used without limitation as long as it is a sequence capable of specifically binding to the LATS1 mutant gene, but is preferably a primer capable of amplifying a region containing a mutation at position 2970 of SEQ ID NO: 1. and, more preferably, the primer may include the sequence represented by SEQ ID NO: 4 or 5.
  • the step of detecting the LATS1 mutant gene is to use a probe that LATS1 mutant binding complementarily to the gene, wherein the probe is complementary to a region containing the mutation position of 2970-th positions in SEQ ID NO: 1 It may be characterized as a binding probe, but is not limited thereto.
  • a reporter may be attached to the 5' end of the probe, and another fluorescent material showing fluorescence may be attached, but is not limited thereto.
  • the reporter may be an enzyme, a fluorescent substance, a ligand, a luminescent substance, a microparticle, a redox molecule, a radioisotope, and the like, but is not limited thereto.
  • the reporter is FAM, JOE, BHQ1, VIC, TAMRA, ROX, NED, HEX, TET, fluorescein, fluorescein chlorotriazinyl, rhodamine green ), rhodamine red, tetramethylrhodamine, FITC, Oregon green, Alexa Fluor, Texas Red, Cyanine-based dyes and cyanine It may be at least one selected from the group consisting of dicarbocyanine dyes.
  • a black hole quencher-1 (BHQ-1) may be attached to the 3' end of the probe as a quencher, and other materials that can be used as a quencher may be attached thereto. Not limited.
  • the quencher may be selected from the group consisting of Dabcyl, TAMRA, Eclipse, DDQ, QSY, Blackberry Quencher, Qxl, Iowa black FQ, Iowa black RQ and IRDye QC-1. It may be one or more selected.
  • the primer set and probe can be used for real time polymerase chain reaction (PCR), and more preferably, can be used for multiplex real time PCR.
  • PCR polymerase chain reaction
  • the nucleic acid sequence contained in the probe or primer may also be modified using a number of means known in the art.
  • Non-limiting examples of such modifications include methylation, "encapsulation", substitution of one or more homologues of natural nucleotides, and modifications between nucleotides, such as uncharged linkages (eg, methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.) or charged linkages (eg phosphorothioates, phosphorodithioates, etc.).
  • uncharged linkages eg, methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.
  • charged linkages eg phosphorothioates, phosphorodithioates, etc.
  • the step of detecting the LATS1 mutant gene is a polymerase chain reaction, nucleic acid digestion (nuclease digestion), hybridization (hybridization), Southern blotting (Southern blotting), restriction enzyme fragment polymorphism (restriction) Enzyme fragment polymorphism), primer extension (primer extension), single stranded conformation polymorphism, DNA chip (DNA chip), microarray (Microarray) and a method selected from the group consisting of a combination thereof to analyze using It may be characterized, but is not limited thereto, and in addition to the above method, it may be analyzed using a known molecular biological method together.
  • the "simultaneous multiplex PCR” means that two or more sets of primers used for PCR are used in one amplification reaction.
  • a “primer” is a short single-stranded oligonucleotide that serves as a starting point for DNA synthesis.
  • a primer binds specifically to a polynucleotide as a template under suitable buffer and temperature conditions, and DNA polymerase adds a nucleoside triphosphate having a base complementary to the template DNA to the primer to link it. is synthesized
  • a primer generally consists of a sequence of 15 to 30 bases, but is not limited thereto, and the temperature (melting temperature, Tm) at which it binds to the template strand varies depending on the base composition and length.
  • Probe refers to a fragment of a polynucleotide such as RNA or DNA with a length of several to several hundred base pairs that can specifically bind to mRNA or cDNA (complementary DNA) of a specific gene. and the presence or absence and expression level of the target mRNA or cDNA to be bound by labeling can be confirmed.
  • the probe specifically binds to the LATS1 mutant gene, preferably, it is characterized in that it specifically binds to a site containing the mutation of the LATS1 gene, most preferably the LATS1 gene of SEQ ID NO: 1 It is characterized in that it specifically binds to a site including a site in which the 2790th base is deleted.
  • the th amino acid was substituted with phenylalanine (Phe) from leucine (Leu), and it was confirmed that protein synthesis was terminated at the 27 th amino acid (956 th) from this (SEQ ID NO: 3). Therefore, when a LATS1 mutant protein encoded by the LATS1 mutant gene is detected from a sample isolated from an individual, amyotrophic lateral sclerosis can be diagnosed.
  • the 930th amino acid is substituted from leucine (Leu) to phenylalanine (Phe), and from this, the 27th amino acid (956) It may be characterized in that protein synthesis is terminated in the second), and preferably it may be characterized as a protein represented by the amino acid sequence of SEQ ID NO: 3.
  • the detecting of the LATS1 mutant protein encoded by the LATS1 mutant gene may be characterized in that it is detected using an antibody or aptamer specific for the protein.
  • the step of detecting the LATS1 mutant protein encoded by the LATS1 mutant gene is Western blotting, ELISA, radioimmunoassay, radioimmunodiffusion method, Ouchterlony immunodiffusion method, rocket immunoelectrophoresis, immunization
  • the detection may be characterized by using a method selected from the group consisting of histochemical staining, immunoprecipitation analysis, complement fixation analysis, FACS, protein chip, and combinations thereof.
  • antibody refers to an immunoglobulin that specifically binds to an antigenic site.
  • Antibodies for use in the present invention include monoclonal or polyclonal antibodies, immunologically active fragments (eg, Fab or (Fab)2 fragments), antibody heavy chains, humanized antibodies, antibody light chains, genetically engineered single chain Fv molecules, a chimeric antibody or the like. All immunoglobulin antibodies, antigen-binding sites and fragments thereof that specifically bind to the LATS1 mutant protein encoded by the LATS1 mutant gene are included.
  • the antibody specifically binds to the mutant LATS1 protein encoded by the mutant LATS1 gene, and preferably, in the amino acid sequence of SEQ ID NO: 2, amino acid at position 930 is substituted from leucine (Leu) to phenylalanine (Phe) From this, it may be an antibody that specifically binds to a protein whose protein synthesis is terminated at the 27th amino acid (956th) or a protein represented by the amino acid sequence of SEQ ID NO: 3.
  • aptamer refers to a small single-stranded oligonucleic acid capable of specifically recognizing a target material with high affinity as a single-stranded DNA or RNA molecule. Aptamers can be used as one element of a biosensor capable of recognizing molecules in a detection and analysis system, and thus has been recognized as an antibody substitute. In particular, unlike antibodies, aptamers can be used as target molecules of various organic and inorganic substances, including toxins, and once an aptamer that specifically binds to a specific substance is isolated, it is reproduced at low cost and consistency by an automated oligomer synthesis method. This was possible and economical.
  • the aptamer specifically binds to the LATS1 mutant protein encoded by the LATS1 mutant gene, and preferably, in the amino acid sequence of SEQ ID NO: 2, the 930th amino acid is substituted from leucine (Leu) to phenylalanine (Phe) and, from this, it may be an aptamer that specifically binds to a protein whose protein synthesis is terminated at the 27th amino acid (956th) or a protein represented by the amino acid sequence of SEQ ID NO:3.
  • the biological sample is a nucleic acid sample isolated from a sample selected from the group consisting of blood, hair, saliva, urine, semen, vaginal cells, oral cells, placental cells or amniotic fluid containing fetal cells and mixtures thereof.
  • the nucleic acid may be genomic DNA, cell free DNA (cfDNA), RNA or micro RNA, but is not limited thereto.
  • the nucleic acid can be obtained through a conventional method known in the art.
  • the tissue is treated with a DNA lysis buffer (e.g., tris-HCl, EDTA, EGTA, SDS, deoxycholate, and tritonX and/or NP-40) to isolate DNA.
  • a DNA lysis buffer e.g., tris-HCl, EDTA, EGTA, SDS, deoxycholate, and tritonX and/or NP-40
  • the present invention is not limited thereto.
  • the information providing method or diagnostic method can be used alone for the diagnosis of amyotrophic lateral sclerosis, and in addition to the detection of the LATS1 gene of the present invention, it can be used in combination with the detection of other genes or proteins known as diagnostic markers of amyotrophic lateral sclerosis. have.
  • nerve conduction velocity test NCV
  • muscle tissue biopsy blood test, urine test, cerebrospinal fluid test, cervical spine X-ray and magnetic resonance imaging test
  • EMG electromyography
  • the present invention provides a diagnostic marker for amyotrophic lateral sclerosis, a single nucleotide variant (SNV), an insertion or deletion (Indel), and any one or more of a copy-number variation (CNV). It relates to a LATS1 (Large Tumor Suppressor Kinase 1) mutant gene, including.
  • SNV single nucleotide variant
  • Indel insertion or deletion
  • CNV copy-number variation
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that insertion or deletion occurs.
  • the LATS1 (Large tumor suppressor kinase 1) mutant gene may be characterized in that one or more of the nucleotides of the gene are deleted.
  • the LATS1 gene may be characterized in that it comprises a nucleotide sequence represented by SEQ ID NO: 1.
  • the LATS1 (Large tumor suppressor kinase 1) mutant gene may be characterized in that the mutation occurs at the 2790th base in the nucleotide sequence of SEQ ID NO: 1.
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that the 2790th nucleotide is deleted from the nucleotide sequence of SEQ ID NO: 1.
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that a frame shift occurs due to mutation.
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that a frame shift mutation occurs by deletion of the 2790 th nucleotide in the nucleotide sequence of SEQ ID NO: 1.
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that the 2790th nucleotide is deleted from the nucleotide sequence of SEQ ID NO: 1.
  • the present invention provides a diagnostic marker for amyotrophic lateral sclerosis, a single nucleotide variant (SNV), an insertion or deletion (Indel), and a copy-number variation (CNV) any one It relates to a LATS1 mutant protein encoded by a large tumor suppressor kinase 1 ( LATS1 ) mutant gene including the above.
  • SNV single nucleotide variant
  • Indel insertion or deletion
  • CNV copy-number variation
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that insertion or deletion occurs.
  • the LATS1 (Large tumor suppressor kinase 1) mutant gene may be characterized in that one or more of the nucleotides of the gene are deleted.
  • the LATS1 gene may be characterized in that it comprises a nucleotide sequence represented by SEQ ID NO: 1.
  • the LATS1 (Large tumor suppressor kinase 1) mutant gene may be characterized in that the mutation occurs at the 2790th base in the nucleotide sequence of SEQ ID NO: 1.
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that the 2790th nucleotide is deleted from the nucleotide sequence of SEQ ID NO: 1.
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that a frame shift occurs due to mutation.
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that a frame shift mutation occurs by deletion of the 2790 th nucleotide in the nucleotide sequence of SEQ ID NO: 1.
  • the LATS1 (Large Tumor Suppressor Kinase 1) mutant gene may be characterized in that the 2790th nucleotide is deleted from the nucleotide sequence of SEQ ID NO: 1.
  • the LATS1 mutant protein is that in the amino acid sequence of SEQ ID NO: 2, the 930th amino acid is substituted from leucine (Leu) to phenylalanine (Phe), and protein synthesis is terminated at the 27th amino acid (956th) therefrom. It may be characterized, and preferably, it may be characterized as represented by the amino acid sequence of SEQ ID NO: 3.
  • the term "diagnostic marker” refers to an organic biomolecule that is a substance that can distinguish cancer patients from healthy people and diagnose them, and shows an increase in cancer-causing individuals compared to healthy people.
  • the organic biomolecules include, but are not limited to, polypeptides, proteins, nucleic acids, lipids, glycolipids, glycoproteins, and sugars.
  • the organic biomolecule refers to DNA, RNA, polypeptide or protein.
  • the diagnostic marker is a LATS1 mutant gene or a LATS1 mutant protein encoded by the gene.
  • the present invention relates to a diagnostic composition for amyotrophic lateral sclerosis comprising an agent capable of detecting a large tumor suppressor kinase 1 ( LATS1 ) mutant gene or a LATS1 mutant protein encoded by a mutant LATS1 gene.
  • LATS1 large tumor suppressor kinase 1
  • the preparation may include a primer capable of specifically amplifying the mutation site of the LATS1 gene or a probe that complementarily binds to the region including the mutation site of the LATS1 gene. have.
  • the preparation may include an antibody or aptamer specific for the LATS1 mutant protein.
  • the primer can be used without limitation as long as it is a sequence that can specifically bind to the LATS1 mutant gene, but is preferably a primer capable of amplifying a site containing a mutation at position 2970 of SEQ ID NO: 1. . More preferably, it may be characterized in that it is capable of amplifying a site containing a deletion at position 2970 of SEQ ID NO: 1, and most preferably, the primer comprises the nucleotide sequence represented by SEQ ID NO: 4 or 5 can be characterized as
  • the probe specifically binds to the LATS1 mutant gene, preferably, it is characterized in that it specifically binds to a site containing the mutation of the LATS1 gene, most preferably the LATS1 gene of SEQ ID NO: 1 It may be characterized in that it specifically binds to a site including a site in which the 2790th base of the is deleted.
  • the antibody specifically binds to the LATS1 mutant protein encoded by the LATS1 mutant gene, and preferably, in the amino acid sequence of SEQ ID NO: 2, the 930th amino acid is leucine (Leu) to phenylalanine ( Phe), and from which protein synthesis is terminated at the 27th amino acid (956th), it may be an antibody that specifically binds to a protein represented by the amino acid sequence of SEQ ID NO:3.
  • the aptamer specifically binds to the LATS1 mutant protein encoded by the LATS1 mutant gene, and preferably, in the amino acid sequence of SEQ ID NO: 2, the 930th amino acid is leucine (Leu) to phenylalanine (Phe) It may be an aptamer that specifically binds to a protein in which protein synthesis is terminated at the 27th amino acid (956th) or a protein represented by the amino acid sequence of SEQ ID NO:3.
  • the composition may include all of the diagnostic primer, probe, antibody, and aptamer, and may include any combination thereof.
  • the diagnostic composition of the present invention may include a reagent known in the art used for detecting a mutated LATS1 gene or mutated protein for specific diagnosis of amyotrophic lateral sclerosis.
  • the diagnostic composition of the present invention may be provided in a state of being fixed on a suitable carrier or support using various known methods in order to increase the speed and convenience of diagnosis.
  • suitable carriers or supports include agarose, cellulose, nitrocellulose, dextran, sephadex, sepharose, liposome, carboxymethylcellulose, polyacrylamide, polyesterin, gabbro, filter paper, ion exchange resin, plastic. films, plastic tubes, glass, polyamine-methyl vinyl-ether-maleic acid copolymers, amino acid copolymers, ethylene-maleic acid copolymers, nylon, cups, flat packs and the like.
  • Other solid substrates include cell culture plates, ELISA plates, tubes, and polymeric membranes.
  • the support may have any possible shape, for example spherical (bead), cylindrical (test tube or well inner surface), planar (sheet, test strip).
  • the diagnostic composition of the present invention can be used alone for the diagnosis of amyotrophic lateral sclerosis, and other genes or proteins known as diagnostic markers for amyotrophic lateral sclerosis in addition to the detection of the LATS1 gene of the present invention can be used in combination with a composition for detection can
  • a composition for detection can be used in combination with a composition for detection can
  • nerve conduction velocity test (NCV) nerve conduction velocity test
  • muscle tissue biopsy blood test
  • urine test cerebrospinal fluid test
  • cervical spine X-ray and magnetic resonance imaging test electromyography (EMG)
  • EMG electromyography
  • the present invention relates to a kit for diagnosis of amyotrophic lateral sclerosis, comprising an agent capable of detecting a mutant LATS1 (Large tumor suppressor kinase 1) gene or a LATS1 mutant protein encoded by a mutant LATS1 gene.
  • LATS1 Large tumor suppressor kinase 1
  • the kit may include the composition for diagnosis of amyotrophic lateral sclerosis.
  • the preparation may include a primer capable of specifically amplifying the mutation site of the LATS1 gene or a probe that complementarily binds to the region including the mutation site of the LATS1 gene. have.
  • the preparation may include an antibody or aptamer specific for the LATS1 mutant protein.
  • primer can be used without limitation as long as it is a sequence capable of specifically binding to the LATS1 mutant gene, but preferably it may be characterized as a primer capable of amplifying the mutation at position 2970 of SEQ ID NO: 1. Most preferably, the primer may be characterized in that it comprises a nucleotide sequence represented by SEQ ID NO: 4 or 5.
  • the probe specifically binds to the LATS1 mutant gene, preferably, it is characterized in that it specifically binds to a site containing the mutation of the LATS1 gene, most preferably the LATS1 gene of SEQ ID NO: 1 It may be characterized in that it specifically binds to a site including a site in which the 2790th base of the is deleted.
  • the antibody specifically binds to the LATS1 mutant protein encoded by the LATS1 mutant gene, and preferably, in the amino acid sequence of SEQ ID NO: 2, the 930th amino acid is leucine (Leu) to phenylalanine ( Phe), from which protein synthesis is terminated at the 27th amino acid (956th); Or it may be an antibody that specifically binds to the protein represented by the amino acid sequence of SEQ ID NO: 3.
  • the aptamer specifically binds to the LATS1 mutant protein encoded by the LATS1 mutant gene, and preferably, in the amino acid sequence of SEQ ID NO: 2, the 930th amino acid is leucine (Leu) to phenylalanine (Phe) a protein from which protein synthesis is terminated at the 27th amino acid (956th); Or it may be an aptamer that specifically binds to the protein represented by the amino acid sequence of SEQ ID NO: 3.
  • the kit may further include one or more other component compositions, solutions, or devices suitable for the analysis method as well as primers, probes, antibodies, etc. for diagnosing amyotrophic lateral sclerosis, preferably RT - It may be in the form of a PCR kit, a microarray chip kit, a DNA chip kit, or a protein chip kit, but is not limited thereto.
  • the kit for measuring the mRNA expression level of the marker genes in the present invention may be a kit including essential elements necessary for performing RT-PCR.
  • the RT-PCR kit includes a test tube or other suitable container, reaction buffer, deoxynucleotides (dNTPs), enzymes such as Taq-polymerase and reverse transcriptase, DNase, RNase inhibitors, DEPC -Water (DEPC-water), sterile water, etc. may be included.
  • the kit of the present invention may be a kit including essential elements necessary for performing a microarray.
  • the microarray kit includes a substrate to which cDNA corresponding to a gene or fragment thereof is attached as a probe, and the substrate may include cDNA corresponding to a quantitative control gene or fragment thereof. It can be easily prepared by a manufacturing method commonly used in In order to fabricate a microarray, a micropipetting method using a piezoelectric method or a pin type to immobilize the detected marker on a substrate of a DNA chip using the probe DNA molecule It is preferable to use a method using a spotter, but is not limited thereto.
  • the substrate of the microarray chip is preferably coated with an active group selected from the group consisting of amino-silane, poly-L-lysine and aldehyde, but is not limited thereto.
  • the substrate is preferably selected from the group consisting of slide glass, plastic, metal, silicon, nylon membrane and nitrocellulose membrane, but is not limited thereto.
  • the kit of the present invention may be a kit including essential elements necessary for performing a DNA chip.
  • the DNA chip kit may include a substrate to which cDNA or oligonucleotide corresponding to a gene or fragment thereof is attached, and reagents, agents, enzymes, etc. for preparing a fluorescent probe.
  • the substrate may also contain cDNA or oligonucleotides corresponding to control genes or fragments thereof.
  • the kit may further include, without limitation, an agent for detecting a diagnostic marker of amyotrophic lateral sclerosis known to those of ordinary skill in the art, in addition to the agent.
  • the diagnostic kit of the present invention can be used alone for the diagnosis of amyotrophic lateral sclerosis, and in addition to the detection of the LATS1 gene of the present invention, other genes or proteins known as diagnostic markers for amyotrophic lateral sclerosis can be used in combination with a kit for detection can
  • a kit for detection can be used in combination with kits for detection can
  • nerve conduction velocity test (NCV) nerve conduction velocity test
  • muscle tissue biopsy blood test
  • urine test cerebrospinal fluid test
  • cervical spine X-ray and magnetic resonance imaging test Cerbrospinal fluid test
  • EMG electromyography
  • the present invention relates to a diagnostic use of amyotrophic lateral sclerosis of a large tumor suppressor kinase 1 ( LATS1 ) mutant gene and a LATS1 mutant protein encoded by the gene, including any one or more of SNV, Indel and CNV. will be.
  • LATS1 large tumor suppressor kinase 1
  • the present invention in the isolated biological sample, LATS1 (Large tumor suppressor kinase 1) mutant gene or amyotrophic lateral sclerosis comprising the step of detecting a mutant LATS1 protein encoded by the mutant LATS1 gene It relates to a diagnostic method for sclerosis: ALS.
  • LATS1 Large tumor suppressor kinase 1
  • ALS amyotrophic lateral sclerosis
  • ALS sporadic ALS who visited Hanyang University Neurology ALS Clinic were included in the ALS trio study. The patient was born in Korea. For clinical diagnosis, a neurological evaluation including electromyography, clinical examination, and appropriate imaging methods was performed on the patient. All ALS patients were diagnosed by a neurologist specializing in neuromuscular disease, and it was confirmed that they met the revised El Escorial diagnostic criteria (reference required). Such as spinal muscular atrophy, Kennedy syndrome, monomelic atrophy, Hirayama syndrome and multifocal motor neuropathy not considered in the ALS spectrum Patients diagnosed with the condition were excluded from the study.
  • ALSFRS-R was used to determine the extent of functional impairment for diagnosis by physicians.
  • ALSFRS-R includes language skills, salivation, swallowing, handwriting, food cutting and instrumentation (with or without gastrostomy), dressing and hygiene, bed rotation and futon adjustment, walking, stair climbing, dyspnea, and orthepnea. ) and 12 questions assessing respiratory failure. Scores for each item were summed to give a score between 0 and 48. Progression rate was calculated as ⁇ FS (48-ALSFRS-R at diagnosis/time from onset to diagnosis), and patients were divided into three groups [slow (cut-off value ⁇ 0.66), medium (0.66-1.00), and fast (>1.00)].
  • Genomic DNA was isolated from peripheral blood leukocytes using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI) according to the manufacturer's instructions. DNA was confirmed by 1% agarose gel electrophoresis and PicoGreen® dsDNA Assay (Invitrogen, Life Technologies, Waltham, Mass.). As far as possible, the DNA should be intact with an OD 260/280 ratio of 1.8-2.0.
  • the SureSelect sequencing library was prepared according to the manufacturer's instructions using the Agilent SureSelect all Exon kit 50Mb (Agilent, Santa Clara, CA) with The Bravo automated liquid handler.
  • the sequencing adapter was ligated to the DNA fragment according to the manufacturer's protocol (Agilent).
  • the adapter bound to the DNA was amplified using PCR.
  • the quality of the PCR product was evaluated by capillary electrophoresis (Bioanalyzer, Agilent).
  • SureSelect hyb #1, #2, #3, and #4 reagents (Agilent) were mixed to make the hybridization buffer.
  • the amplified DNA fragment was concentrated to 750 ng in 3.4 ⁇ l.
  • SureSelect block #1, #2, and #3 reagents (Agilent) were added to 750 ng of DNA.
  • Hybridization buffer and DNA blocker mix were incubated at 95°C for 5 minutes and then at 65°C for 10 minutes using a gene amplifier.
  • the RNase block (Agilent) was added to the SureSelect oligo capture library (Agilent).
  • the capture library was incubated at 65° C. for 2 minutes.
  • hybridization buffer and then DNA blocker mix were added to the capture library, and the mixture was incubated at 65° C. for 24 hours using a gene amplifier.
  • Dynal MyOne Streptavidin T1 (Invitrogen) coated with 50 ml streptavidin was washed three times with 200 ml SureSelect binding buffer (Agilent), and then resuspended in 200 ⁇ l binding buffer.
  • the hybridization mixture was added to the bead suspension and incubated for 30 minutes while mixing at room temperature.
  • Captured libraries were amplified to add index tags using Herculase II Fusion DNA Polymerase (Finnzymes, Life Technologies). The quality of the amplified library was evaluated by capillary electrophoresis (Bioanalyzer, Agilent). QPCR was performed using SYBR Green PCR Master Mix (Applied Biosystems, Life Technologies), and then 6 libraries tagged at equimolar amounts in the pool were combined. Cluster formation was performed using a cBot automated cluster generation system (illumine, San Diego, CA) and sequencing was performed with a unit length of 2x100 bp using a HiSeq 2500 sequencing system (illumina).
  • the reads were mapped to the GRCh37/hg19 build using a Burrows-Wheeler Aligner (BWA) 0.7.10.
  • Picard-tools 1.114 was used to display duplicate reads (http://picard.sourceforge.net/).
  • a GATK (v3.2-2) IndelRealigner was used to reconcile reads around insertion or deletion (indel) positions.
  • the quality of the read results was measured using the GATK BaseRecalibrator. Genotypes were generated simultaneously for all samples by the GATK HaplotypeCaller. Variant quality score adjustment was performed using GATK VariantRecalibrator, and was filtered with 99.7 truth sensitivity level.
  • dbSNP 1000 Genomes Project (http://www.1000genomes.org/), and gnomAD (http://http://gnomad.broadinstitute.org/) were identified. Annotation of mutations was performed using an in-house custom-made script (Table 1).
  • the novel mutation was confirmed that the parent was homozygous for the reference sequence, and the initiator was heterozygous.
  • KRGDB Korean Reference Genome Database, http://coda.nih.go.kr/coda/KRGDB/index.jsp
  • Novel mutations leading to substitution of all amino acids according to the filtering criteria were evaluated by Sanger sequencing of paternal, maternal and progenitor DNA samples. All exon and exon-intron boundaries of the target gene were amplified by PCR using primers (Table 6). PCR was performed using the gene amplifier model GeneAmp PCR system 9700 (Applied Biosytems, Foster City, CA) under the following conditions: 32 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 30 seconds. .
  • the amplicon (5 ⁇ l) was treated with 2U shrimp alkaline phosphatase and 10U exonuclease I (USB Corp., Cleveland, OH) at 37°C for 15 minutes, and then incubated at 80°C for 15 minutes to inactivate the enzyme. did it Cycle sequencing was performed using the Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster City, CA, USA) in ABI 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
  • Mutations were named according to the reference sequence of GenBank.
  • the notation for mutation in the present invention followed the recommendation of the Human Genome Mutation Association (http://www.hgvs.org/mutnomen/) in which the nucleotide corresponding to A of the ATG start codon is denoted by +1.
  • Example 1 Descriptive statistics for Q.C analysis and exome sequencing
  • VUS unknown significance
  • the present inventors discovered one novel variants of unknown significance (VUS) from the sALS trio ( FIGS. 2 and 3 ).
  • the 2790th nucleotide sequence of the LATS1 gene is deleted, leucine, the 930th amino acid among the amino acid sequence of the normal protein LATS1 having the amino acid sequence of SEQ ID NO: 2, is substituted with phenylalanine, and protein synthesis occurs at the 27th (956th) from there.
  • the frameshift mutation that ends.
  • the LATS1 mutant protein expressed by mutation of the LATS1 gene is represented by the amino acid sequence of SEQ ID NO: 3.
  • the present invention provides an accurate and efficient marker-based diagnostic method for diagnosing amyotrophic lateral sclerosis that lacks effective molecular diagnostic markers.
  • the marker of the present invention can diagnose amyotrophic lateral sclerosis even when a previously reported marker is not found, and suggests a new diagnostic method for amyotrophic lateral sclerosis.
  • the diagnostic method, marker, and use thereof of the present invention are useful in the diagnosis, prediction, treatment and prevention of amyotrophic lateral sclerosis.
  • the LATS1 gene of the present invention can be used to study the onset mechanism of amyotrophic lateral sclerosis and develop a drug for treatment.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de diagnostic de la sclérose latérale amyotrophique sur la base d'une mutation du gène LATS1. La présente invention concerne un procédé de diagnostic basé sur un marqueur précis et efficace pour diagnostiquer la sclérose latérale amyotrophique pour laquelle des marqueurs de diagnostic moléculaire efficaces sont insuffisants. Le marqueur de la présente invention permet le diagnostic de la sclérose latérale amyotrophique même lorsqu'aucun des marqueurs signalés au préalable n'est observé, et suggère un nouveau procédé de diagnostic pour la sclérose latérale amyotrophique. Le procédé de diagnostic, le marqueur, et leur utilisation selon la présente invention sont très avantageux pour le diagnostic, la prédiction, le traitement et la prévention de la sclérose latérale amyotrophique. En outre, le gène LATS1 de la présente invention peut être utilisé pour étudier le mécanisme pathologique de la sclérose latérale amyotrophique et pour développer un médicament pour la sclérose latérale amyotrophique.
PCT/KR2020/017169 2019-11-29 2020-11-27 Procédé de diagnostic de la sclérose latérale amyotrophique sur la base d'un marqueur de mutation du gène lats1 WO2021107713A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0157258 2019-11-29
KR1020190157258A KR102294939B1 (ko) 2019-11-29 2019-11-29 Lats1 유전자 변이 마커 기반의 근위축성 측삭경화증의 진단방법

Publications (1)

Publication Number Publication Date
WO2021107713A1 true WO2021107713A1 (fr) 2021-06-03

Family

ID=76129754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/017169 WO2021107713A1 (fr) 2019-11-29 2020-11-27 Procédé de diagnostic de la sclérose latérale amyotrophique sur la base d'un marqueur de mutation du gène lats1

Country Status (2)

Country Link
KR (1) KR102294939B1 (fr)
WO (1) WO2021107713A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117625632A (zh) * 2024-01-22 2024-03-01 中国医学科学院北京协和医院 肌萎缩侧索硬化症的SQSTM1的p.L382CfsTer13突变致病基因及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160200697A1 (en) * 2013-08-28 2016-07-14 University of Pittsburgh - of the Commonwealth Sys tem of Higher Education Inhibition of wnt, tgf beta and hippo signaling pathways to treat cancer, organ fibrosis and metabolic disorders
KR20170041955A (ko) * 2015-10-07 2017-04-18 사회복지법인 삼성생명공익재단 근위축성측삭경화증에 대한 진단 마커로서의 돌연변이 유전자 및 이를 이용한 진단방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160200697A1 (en) * 2013-08-28 2016-07-14 University of Pittsburgh - of the Commonwealth Sys tem of Higher Education Inhibition of wnt, tgf beta and hippo signaling pathways to treat cancer, organ fibrosis and metabolic disorders
KR20170041955A (ko) * 2015-10-07 2017-04-18 사회복지법인 삼성생명공익재단 근위축성측삭경화증에 대한 진단 마커로서의 돌연변이 유전자 및 이를 이용한 진단방법

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KIM EUN-JOO; KIM YOUNG-EUN; JANG JA-HYUN; CHO EUN-HAE; NA DUK L.; SEO SANG WON; JUNG NA-YEON; JEONG JEE H.; KWON JAY C.; PARK KEE : "Analysis of frontotemporal dementia, amyotrophic lateral sclerosis, and other dementia-related genes in 107 Korean patients with frontotemporal dementia", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 72, 30 June 2018 (2018-06-30), US, XP085523045, ISSN: 0197-4580, DOI: 10.1016/j.neurobiolaging.2018.06.031 *
KIM YOUNG-HO, OHTA TAKASHI, OH JI EUN, LE CALVEZ-KELM FLORENCE, MCKAY JAMES, VOEGELE CATHERINE, DURAND GEOFFROY, MITTELBRONN MICHE: "TP53, MSH4, and LATS1 Germline Mutations in a Family with Clustering of Nervous System Tumors", AMERICAN JOURNAL OF PATHOLOGY., ELSEVIER INC., US, vol. 184, no. 9, 1 September 2014 (2014-09-01), US, pages 2374 - 2381, XP055816178, ISSN: 0002-9440, DOI: 10.1016/j.ajpath.2014.05.017 *
OH JI-EUN, OHTA TAKASHI, SATOMI KAISHI, FOLL MATTHIEU, DURAND GEOFFROY, MCKAY JAMES, CALVEZ-KELM FLORENCE LE, MITTELBRONN MICHEL, : "Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, LIPPINCOTT WILLIAMS AND WILKINS., NEW YORK, NY., vol. 74, no. 10, 1 October 2015 (2015-10-01), NEW YORK, NY., pages 952 - 959, XP055816173, ISSN: 0022-3069, DOI: 10.1097/NEN.0000000000000238 *
SAADELDIN MONA K., SHAWER HEBA, MOSTAFA AHMED, KASSEM NEEMAT M., AMLEH ASMA, SIAM RANIA: "New genetic variants of LATS1 detected in urinary bladder and colon cancer", FRONTIERS IN GENETICS, vol. 5, no. 425, 1 January 2015 (2015-01-01), pages 1 - 11, XP055816185, DOI: 10.3389/fgene.2014.00425 *
TATE GENSHU; KISHIMOTO KOJI; MITSUYA TOSHIYUKI: "Biallelic alterations of thelarge tumor suppressor 1(LATS1) gene in infiltrative, but not superficial, basal cell carcinomas in a Japanese patient with nevoid basal cell carcinoma syndrome", MEDICAL MOLECULAR MORPHOLOGY, SPRINGER JAPAN, TOKYO, vol. 48, no. 3, 14 August 2014 (2014-08-14), Tokyo, pages 177 - 182, XP035544925, ISSN: 1860-1480, DOI: 10.1007/s00795-014-0086-8 *
YU TIAN; BACHMAN JOHN; LAI ZHI-CHUN: "Mutation analysis of large tumor suppressor genesLATS1andLATS2supports a tumor suppressor role in human cancer", PROTEIN & CELL, SPRINGER ASIA, BEIJING, CN, vol. 6, no. 1, 9 December 2014 (2014-12-09), Beijing, CN, pages 6 - 11, XP035734463, ISSN: 1674-800X, DOI: 10.1007/s13238-014-0122-4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117625632A (zh) * 2024-01-22 2024-03-01 中国医学科学院北京协和医院 肌萎缩侧索硬化症的SQSTM1的p.L382CfsTer13突变致病基因及其应用

Also Published As

Publication number Publication date
KR20210067530A (ko) 2021-06-08
KR102294939B1 (ko) 2021-08-30

Similar Documents

Publication Publication Date Title
Koch et al. TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E
KR101719376B1 (ko) 연령-관련 황반 변성에서 유전자 다형성
WO2015156519A1 (fr) Procédé de prédiction d'une réaction au traitement par le sorafénib à l'aide du polymorphisme génique
WO2019199105A1 (fr) Procédé d'évaluation du risque de maladie d'alzheimer
CA2922005A1 (fr) Procedes et compositions de depistage et de traitement de troubles du developpement
WO2021029473A1 (fr) Kit de diagnostic pharmacogénomique à grande vitesse pour pharmacothérapie personnalisée et prédiction des effets secondaires de multiples médicaments de prescription associés au cancer et à des maladies chroniques
JP2011509096A (ja) 特発性自閉症のリスク増加に関連するコンタクション関連タンパク質２（ｃｎｔｎａｐ２）の突然変異
Apessos et al. Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center
WO2021107713A1 (fr) Procédé de diagnostic de la sclérose latérale amyotrophique sur la base d'un marqueur de mutation du gène lats1
WO2020231081A1 (fr) Procédé de diagnostic de la démence basé sur la mutation du gène top3b
WO2020209590A1 (fr) Composition pour le diagnostic ou la prédiction pronostique d'un gliome, et procédé pour fournir des informations lui étant associées
WO2020060170A1 (fr) Composition de marqueur pour le diagnostic de dermatite atopique et procédé, utilisant celle-ci, pour la prédiction ou le diagnostic de dermatite atopique
WO2017007275A1 (fr) Composition pour la détermination d'un phénotype nasal
WO2019132581A1 (fr) Composition de diagnostic du cancer, tel que du cancer du sein et du cancer de l'ovaire, et son utilisation
WO2022114526A1 (fr) Marqueur de polymorphisme mononucléotidique permettant de prédire un risque de maladie d'alzheimer et son utilisation
Bisht et al. Molecular combing solutions to characterize replication kinetics and genome rearrangements
WO2011159004A1 (fr) Snp destiné à prédire la sensibilité à une formulation thérapeutique anticancéreuse ciblée
WO2021025412A1 (fr) Méthode de diagnostic de la maladie d'alzheimer au moyen du composant c8 gamma du complément
WO2020204313A1 (fr) Marqueur snp pour diagnostiquer un anévrisme cérébral, comprenant un polymorphisme monobasique du gène gba
WO2022030840A1 (fr) Marqueur de polymorphisme mononucléotidique pour le diagnostic d'une néphropathie à immunoglobulines a, d'une vascularite à immunoglobulines a et procédé de diagnostic l'utilisant
WO2019225803A1 (fr) Association entre un polymorphisme de nucléotide simple de rnf213 et un risque de développer une maladie de moyamoya chez les coréens
WO2011118967A2 (fr) Polymorphisme mononucléotidique pour pronostiquer un carcinome hépatocellulaire
WO2017065335A1 (fr) Gène park2 mutant et procédé pour le diagnostic de la maladie de parkinson l'utilisant
KR102387354B1 (ko) 샤르코-마리-투스병 진단용 마커 및 그의 용도
RU2768033C1 (ru) Способ дифференциальной и подтверждающей молекулярно-генетической диагностики нейросенсорной тугоухости в популяции чувашей

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20892594

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20892594

Country of ref document: EP

Kind code of ref document: A1